Showing 1831-1840 of 3038 results for "".
- Novartis’ Sandoz Unit Confirms Late-Stage Clinical Development Plans for Proposed Biosimilar Aflibercepthttps://modernod.com/news/novartis-sandoz-unit-confirms-late-stage-clinical-development-plans-for-proposed-biosimilar-aflibercept/2479166/Sandoz, a division of Novartis, announced progress in the late-stage clinical development program for its proposed biosimilar aflibercept. Sandoz will begin enrolling the first patient in MYLIGHT, a clinical phase 3 confirmatory efficacy and safety study, shortly.1 Aflibercept (
- Novartis: Phase 3 Beovu Data Show Potential for Fluid Resolution in More DME Patients With Fewer Injections Versus Aflibercepthttps://modernod.com/news/novartis-phase-3-beovu-data-show-potential-for-fluid-resolution-in-more-dme-patients-with-fewer-injections-versus-aflibercept/2479150/Novartis announced positive 1-year results of the phase III KESTREL and KITE studies, evaluating the efficacy and safety of Beovu (brolucizumab-dbll) 6 mg in diabetic macular edema (DME). Both studies met their primary endpoints of noninferiority in change in best corrected visual acuity (
- Nova Eye Medical Announces First Patient Enrolled in MAGIC Multicenter Canaloplasty Trial for Glaucomahttps://modernod.com/news/nova-eye-medical-announces-first-patient-enrolled-in-magic-multicenter-canaloplasty-trial-for-glaucoma/2479145/Nova Eye Medical Limited announced the enrollment of the first glaucoma patient in the multicenter ab-interno glaucoma study investigating canaloplasty (MAGIC) trial. The first MAGIC patie
- Novaliq Announces More Than Half of Patients Enrolled in CyclASol Phase 3 Dry Eye Disease Trial ESSENCE-2https://modernod.com/news/novaliq-announces-more-than-half-of-patients-enrolled-in-cyclasol-phase-3-dry-eye-disease-trial-essence-2/2479125/Novaliq announced today that the second Phase 3 clinical trial evaluating CyclASol to treat the signs and symptoms of dry eye disease (DED) has randomized more than 50% out of 834 targeted patients, with top-line results expected in the second half of 2021. The Phase 3 program for CyclASol
- US Patent Office Issues Notice of Allowance for Nicox’s Latanoprostene Bunod in Normal Tension Glaucomahttps://modernod.com/news/us-patent-office-issues-notice-of-allowance-for-nicoxs-latanoprostene-bunod-in-normal-tension-glaucoma/2479119/Nicoy announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the U.S. patent covering the use of latanoprostene bunod for the treatment of normal tension glaucoma. Latanoprostene bunod ophthalmic solution, 0.024%, is commercialized as Vyzulta for
- Nova Eye: 24-Month iTrack Data Demonstrate Real-World Efficacy of Canaloplasty as Both a Standalone and Combined MIGS Procedurehttps://modernod.com/news/nova-eye-24-month-itrack-data-demonstrate-real-world-efficacy-of-canaloplasty-as-both-a-standalone-and-combined-migs-procedure/2479091/Nova Eye Medical is reporting the peer-reviewed publication of 24-month data for its proprietary iTrack minimally invasive glaucoma surgery (MIGS) technology. Published in Clinical Oph
- Bausch + Lomb Announces Topline Results From The First Phase 3 Trial Of NOV03 In Dry Eye Disease Associated With MGDhttps://modernod.com/news/bausch-lomb-announces-topline-results-from-the-first-phase-3-trial-of-nov03-in-dry-eye-disease-associated-with-mgd/2479072/Bausch + Lomb and Novaliq announced statistically significant topline data from the first phase 3 trial (GOBI trial) evaluating the investigational drug NOV03 (perfluorohexyloctane) as a first-in-class eye drop with a novel mechanism of action to treat the signs and symptoms of dry eye disease (D
- Alcon Canada Introduces UV Only IOLs for AcrySof IQ PanOptix and AcrySof IQ Vivity Portfolioshttps://modernod.com/news/alcon-canada-introduces-uv-only-iols-for-acrysof-iq-panoptix-and-acrysof-iq-vivity-portfolios/2479066/Alcon has announced the availability of AcrySof IQ PanOptix UV IOL, AcrySof IQ PanOptix Toric UV IOL, AcrySof IQ Vivity UV IOL, and AcrySof IQ Vivity Toric UV IOL as part of the presbyopia-correcting lens portfolio in Canada.1 These next-generation IOLs
- AdaptDx Pro’s On-Board AI Technician Now Speaks in Multiple Languageshttps://modernod.com/news/adaptdx-pros-on-board-ai-technician-now-speaks-in-multiple-languages/2479039/MacuLogix announced its first major software upgrade for its AdaptDx Pro portable dark adaptometer. Once the software is automatically downloaded and installed, the artificial intelligence-driven onboard technician, T
- Outlook Therapeutics Reports Positive Safety Profile from NORSE THREE Study for Lytenavahttps://modernod.com/news/outlook-therapeutics-reports-positive-safety-profile-from-norse-three-study-for-lytenava/2479037/Outlook Therapeutics announced positive topline results from its NORSE THREE open-label safety study evaluating ONS-5010/Lytenava (bevacizumab-vikg) to treat retinal diseases. Topline results from the open-label safety study demonstrated that ONS-5010 showed no unexpecte